Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma

NCT02269995 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2018-11-05

No results posted yet for this study

Summary

This surveillance's objectives are:

1. Unknown adverse reactions
2. Incidences of adverse drug reaction
3. Factors considered to have effect to safety and effectiveness

Conditions

Interventions

DEVICE

E7040

E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .

Sponsors & Collaborators

  • Eisai Co., Ltd.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-06
Primary Completion
2015-05-14
Completion
2015-12-25

Countries

  • Japan

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02269995 on ClinicalTrials.gov